---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125334"
form_type: "8-K"
ticker: "ATRA"
cik: "0001604464"
company_name: "Atara Biotherapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:56:45.141035+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Atara Q3 net loss narrows to $21.9M; tab-cel PDUFA Jan 15, 2025; CLO departs

## Summary
- Net loss $21.9M ($2.93/share) vs $69.8M ($16.40) YoY; revenue rose to $40.2M from $2.1M.
- Cash, equivalents & investments $67.2M; net cash used in ops $4.0M vs $51.3M; cash runway into 2027.
- Tab-cel BLA on track; PDUFA Jan 15, 2025; no advisory committee; potential $60M milestone from Pierre Fabre.
- First patient dosed in ATA3219 NHL study; initial data Q1 2025. Lupus nephritis study start by year-end; data mid-2025.
- Chief Legal Officer Amar Murugan departed Nov 8; consulting role at $250/hr; severance and bonuses tied to tab-cel milestones.

## SEC filing metadata
- accession: 0000950170-24-125334
- form_type: 8-K
- ticker: ATRA
- cik: 0001604464
- company_name: Atara Biotherapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/0000950170-24-125334-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/atra-20241108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125334
- JSON: https://secwatch.observer/filing/0000950170-24-125334.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125334.txt

## Key facts
- Executive change
  Amar Murugan departed as Chief Legal Officer at Atara Biotherapeutics, Inc..
  - Action: departed
  - Role: Chief Legal Officer
  source text: On November 8, 2024, it was agreed that the employment of Amar Murugan, the Company’s Chief Legal Officer, would end effective November 8, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1604464/000095017024125334/0000950170-24-125334-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.